UNASSIGNED: Forty-two consecutive recurrent chalaziosis cases (35 patients) treated with IPL-MGX were enrolled. All patients initially underwent excision with curettage. One week after lesion excision, IPL-MGX were performed at least 3 times. Another set of age- and sex-matched consecutive cases of recurrent chalaziosis, who received excision with curettage, but went without IPL-MGX treatment, were collected to calculate recurrence rate. Treatment efficacy and safety were measured before IPL-MGX treatment and 1 month after the final treatment.
UNASSIGNED: The majority of patients received 4 sessions of IPL-MGX therapy (20 patients; 57.1%) or 3 sessions of IPL-MGX therapy (10 patients; 28.6%), resulting in a lower recurrence rate of 11.4% compared to that of recurrent chalaziosis without IPL-MGX cases (45.6%, P < 0.001). The NIBUT was significantly prolonged from 3.9 ± 1.8 to 5.1 ± 1.7 s at 4 weeks after the final treatment (P = 0.001). Similarly, mean TMH score improved and was statistically significant when compared with baseline (0.17 ± 0.07 vs. 0.21± 0.09; P = 0.008). Furthermore, meibum quality and expressibility scores significantly improved at 4 weeks following the final treatment (both P < 0.001). Other variables, such as intraocular pressure and visual acuity, remained unaffected following treatment.
UNASSIGNED: The combination of IPL treatment and MGX offers a low risk and effective option in decreasing the recurrence rate of recurrent chalaziosis by improving meibomian gland function. IPL-MGX may be considered for first-line treatment in recurrent or refractory cases post excision.
UNASSIGNED:纳入了用IPL-MGX治疗的42例连续复发性结束症病例(35例患者)。所有患者最初都进行了刮除术切除。病灶切除后一周,IPL-MGX进行至少3次。另一组年龄和性别匹配的复发性结束炎连续病例,接受了刮宫切除术的人,但是没有IPL-MGX治疗,收集以计算复发率。在IPL-MGX治疗前和最终治疗后1个月测量治疗效果和安全性。
UNASSIGNED:大多数患者接受4次IPL-MGX治疗(20例;57.1%)或3次IPL-MGX治疗(10例;28.6%),与无IPL-MGX病例的复发性结束症相比,复发率较低,为11.4%(45.6%,P<0.001)。最终治疗后4周,NIBUT从3.9±1.8s显着延长至5.1±1.7s(P=0.001)。同样,与基线相比,平均TMH评分改善且具有统计学意义(0.17±0.07vs.0.21±0.09;P=0.008)。此外,在最终治疗后4周时,meibum质量和可表达性评分显着改善(均P<0.001)。其他变量,如眼压和视力,治疗后不受影响。
UNASSIGNED:IPL治疗和MGX的组合通过改善睑板腺功能,提供了一种低风险和有效的选择,可以降低复发性睑板腺的复发率。IPL-MGX可考虑用于切除后复发或难治性病例的一线治疗。